Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 34,239 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh Ph Patel sold 34,239 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $148.52, for a total value of $5,085,176.28. Following the sale, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $77,746,952.56. This trade represents a 6.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock opened at $152.01 on Thursday. The stock’s 50 day simple moving average is $127.64 and its 200 day simple moving average is $106.78. Protagonist Therapeutics, Inc. has a twelve month low of $54.18 and a twelve month high of $152.70. The company has a market capitalization of $9.84 billion, a price-to-earnings ratio of 147.58 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The firm had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. The business’s revenue was up 3746.8% compared to the same quarter last year. On average, analysts forecast that Protagonist Therapeutics, Inc. will post 4.02 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PTGX shares. Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Wedbush boosted their price objective on Protagonist Therapeutics from $118.00 to $173.00 and gave the stock an “outperform” rating in a research report on Monday. Zacks Research downgraded Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 7th. The Goldman Sachs Group raised Protagonist Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $110.00 to $186.00 in a report on Monday. Finally, Citigroup lifted their price target on Protagonist Therapeutics from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $137.86.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: An analyst article maintained a “Strong Buy” view, citing FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, attractive partnership economics and additional pipeline opportunities. Investors are also watching the FDA’s expected August 2026 Priority Review decision for rusfertide, which could lead to significant milestones and royalty payments from Takeda. The company plans to begin a Phase 2b study of oral IL-17 antagonist PN-881 in the first quarter of 2027. Protagonist Therapeutics: Strong Buy—ICOTYDE FDA Approval and PN-881 Advancement
• Positive Sentiment: A psoriasis-focused stock roundup included PTGX among companies offering exposure to approved therapies, late-stage candidates and earlier-stage psoriasis programs. This reinforces investor interest in Protagonist’s inflammatory-disease pipeline, although the article does not provide a new company-specific catalyst. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear anomalous, they provide little meaningful indication of near-term short-covering or bearish pressure.
• Negative Sentiment: CEO Dinesh V. Patel sold a combined 100,000 shares for approximately $14.9 million in transactions dated August 10 and 11. The sales reduced his reported ownership, which can pressure sentiment; however, both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, making them less indicative of a fresh change in management’s outlook. SEC insider transaction filing

Institutional Investors Weigh In On Protagonist Therapeutics

Several hedge funds have recently made changes to their positions in PTGX. Keating Financial Advisory Services Inc. bought a new position in Protagonist Therapeutics during the second quarter valued at about $30,000. Allworth Financial LP bought a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth approximately $31,000. Farther Finance Advisors LLC lifted its position in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares during the period. Greenline Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter worth approximately $27,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter worth approximately $42,000. Institutional investors own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.